Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of SCTB41 plus SCTB39G with or without standard therapy in advanced malignant solid tumors
CTR20262379Phase 2Active
- Sponsor
- Sinocelltech Group Limited
- Start
- Jul 2026
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of SCTB41 and SCTB39G in Nonhematologic neoplasms (2 arms), sponsored by Sinocelltech Group Limited. Primary endpoints: Dose-limiting toxicity and Recommended phase II dose. Started Jul 2026; status: active.
02
Drugs
SCTB41SCTB39G
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20262379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262379.